Antitumor Activity of Platinum Analogs

Bradner, William T.; Rose, William C.; Huftalen, James B.

doi:10.1016/b978-0-12-565050-2.50014-0

Cited by 40 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One compound in the latter group, 4-carboxyphthalato (1,2-diaminocyclohexane) platinum (II), has now entered clinical trial and there has been one partial response out of eight patients with ovarian cancer, all of whom had previously received cisplatin (Kelsen et al, 1983). However, studies with murine tumours and human xenografts have suggested that tumours resistant to cisplatin are also resistant to carboplatin (Bradner et al, 1980;Wolpert-DeFilippes, 1980;Boven et al, 1985). This is not surprising in view of recent work that shows that cisplatin and carboplatin have the same mechanism of action and that the two compounds differ only in the kinetics of their interaction with DNA (Knox et al, 1986 Patients were only included in the study if they had a histologically confirmed diagnosis of epithelial ovarian cancer and the histologic material was reviewed by a pathologist at the Royal Marsden Hospital.…”

mentioning

confidence: 99%

Cisplatin/carboplatin cross-resistance in ovarian cancer

Gore

Fryatt²,

Wiltshaw³

et al. 1989

Br J Cancer

106

View full text Add to dashboard Cite

mentioning

confidence: 99%

Cisplatin/carboplatin cross-resistance in ovarian cancer

Gore

Fryatt²,

Wiltshaw³

et al. 1989

Br J Cancer

106

View full text Add to dashboard Cite

“…25) Cisplatin was the first platinum coordination drug used to treat testicular and ovarian tumors. 26) Carboplatin, which was developed as a second-generation analog of cisplatin, has demonstrated significantly less nephrotoxicity and emetogenic potential in both preclinical and clinical studies. [27][28][29] Moreover, a phase I trial in Japan showed that the new platinum analogue, TRK-710, has a lesser degree of nephrotoxicity and myelosuppression.…”

mentioning

confidence: 99%

“…[27][28][29] Moreover, a phase I trial in Japan showed that the new platinum analogue, TRK-710, has a lesser degree of nephrotoxicity and myelosuppression. 30) Both cisplatin and carboplatin cause hematopoietic disorders as side effects, [26][27][28][29] and they are administered intravenously.…”

mentioning

confidence: 99%

Release of Cytokines from Human Umbilical Vein Endothelial Cells Treated with Platinum Compounds in vitro

Shi¹,

Inoue²,

Shinozaki³

et al. 1998

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

Endothelial cells (EC) produce cytokines, such as interleukin (IL)-1, IL-6, IL-8 and granulocytemacrophage colony-stimulating factor (GM-CSF). These cytokines have an important role in the proliferation and differentiation of hematopoietic progenitor cells. On the other hand, anticancer agents generally cause hematopoietic disorders. However, little is known about the effects of chemotherapeutic agents on the secretion of cytokines from EC. Therefore, we investigated if treatment with platinum compounds may stimulate EC to secrete cytokines. EC newly isolated from a human umbilical vein were exposed to cisplatin, carboplatin, or TRK-710 for 80 min, then the cells were washed and placed in fresh medium. The levels of cytokines in the fresh medium were measured by the ELISA method, the levels of intracellular hydrogen peroxide (H 2 O 2 ) were measured by flow cytometry, and the rhodamine 123-stained live mitochondria of the EC were observed under a confocal laser microscope. Platinum compounds induced cytokine production in human EC: cisplatin most prominently induced the release of IL-1 and IL-6, and TRK-710 had the greatest ability to induce the release of GM-CSF. Intracellular H 2 O 2 production and IL-8 release were transiently induced immediately after treatment with platinum compounds, leading to IL-1 release when H 2 O 2 production was eliminated. These results may provide new insights into the hematological toxicity induced by anticancer agents and the role of IL-1 and IL-6 secreted from EC in this toxicity.

show abstract

“…The dosages used in the present study were less than the lethal dose for nude mice and about one-third of the LD50 for conventional mice, reported by other investigators (Wilkinson et al, 1978;Bradner et al, 1980;Schurig et al, 1980;Shepherd et al, 1980;Lelieveld et al, 1984). The doses used here are in the right range because they appear equally toxic in terms of mean body weight as a percentage of starting weight.…”

mentioning

confidence: 81%